PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
PDS Biotechnology Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.92−0.21 (-18.89%)
Close on Oct 19, 2026
- Market cap
- $51.01M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
13.7%
8M of 56M shares
Institutional holders
52
15 new, 4 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nant Capital, LLC | 20,336,335 | 19.90% | 13D (active) | Sep 14, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PDSB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,699,315 | 3.04% | $1.50M | +68,226 | 0.00% |
| Quantinno Capital Management LP | 642,177 | 1.15% | $565.82K | New | 0.00% |
| Focus Partners Wealth | 642,177 | 1.15% | $565.82K | New | 0.00% |
| BlackRock, Inc. | 607,639 | 1.09% | $535.39K | +53,591 | 0.00% |
| Geode Capital Management, LLC | 587,139 | 1.05% | $517.41K | −73,089 | 0.00% |
| Vanguard Fiduciary Trust Co | 357,144 | 0.64% | $314.64K | +49,833 | 0.00% |
| Militia Capital Management LLC | 331,800 | 0.59% | $292.35K | New | 0.01% |
| Citadel Advisors LLC | 323,801 | 0.58% | $285.30K | New | 0.00% |
| Morgan Stanley | 313,922 | 0.56% | $276.60K | +310,000 | 0.00% |
| Blair William & Co/Il | 300,000 | 0.54% | $264.33K | – | 0.00% |
| Jane Street Group, LLC | 279,664 | 0.50% | $246.41K | New | 0.00% |
| Renaissance Technologies LLC | 252,200 | 0.45% | $222.21K | +31,400 | 0.00% |
| Inspirion Wealth Advisors, LLC | 188,995 | 0.34% | $165.18K | +7,000 | 0.02% |
| Marshall Wace, Llp | 147,171 | 0.26% | $129.51K | New | 0.00% |
| State Street Corp | 133,333 | 0.24% | $117.48K | – | 0.00% |
| Northern Trust Corp | 126,502 | 0.23% | $111.46K | +17,609 | 0.00% |
| Wells Fargo & Company/Mn | 109,000 | 0.19% | $96.04K | −1,500 | 0.00% |
| Commonwealth Equity Services, LLC | 92,997 | 0.17% | $81.94K | +2,200 | 0.00% |
| Amussen Hunsaker Associates LLC | 70,406 | 0.13% | $62.04K | −4,616 | 0.01% |
| Bank of New York Mellon Corp | 68,491 | 0.12% | $60.35K | −820 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 52 | 8M | 13.7% | 15 / 13 | 7 / 4 | 3M | 0M |
| Q1 2026 | 41 | 5M | 9.0% | 7 / 11 | 9 / 9 | 2M | 3M |
| Q4 2025 | 44 | 8M | 14.1% | 10 / 11 | 13 / 11 | 3M | 1M |
| Q3 2025 | 47 | 6M | 10.0% | 8 / 10 | 14 / 15 | 1M | 3M |
| Q2 2025 | 55 | 7M | 13.3% | 13 / 12 | 13 / 6 | 2M | 2M |
| Q1 2025 | 48 | 8M | 14.7% | 9 / 11 | 12 / 12 | 5M | 1M |
| Q4 2024 | 52 | 4M | 7.6% | 8 / 17 | 15 / 12 | 1M | 1M |
| Q3 2024 | 57 | 4M | 7.8% | 7 / 8 | 21 / 24 | 1M | 2M |
| Q2 2024 | 77 | 6M | 9.8% | 25 / 15 | 26 / 20 | 1M | 4M |
| Q1 2024 | 72 | 8M | 13.9% | 10 / 24 | 23 / 15 | 1M | 1M |
| Q4 2023 | 77 | 8M | 15.1% | 14 / 26 | 17 / 15 | 1M | 1M |
| Q3 2023 | 78 | 8M | 14.0% | 10 / 24 | 26 / 12 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PDSB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,042,050 | 1.86% | $918.15K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 583,951 | 1.04% | $514.52K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 291,913 | 0.52% | $315.27K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 189,911 | 0.34% | $167.33K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 97,931 | 0.17% | $105.77K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 88,419 | 0.16% | $95.49K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 47,619 | 0.09% | $41.96K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 25,695 | 0.05% | $22.64K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 15,312 | 0.03% | $16.54K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 12,794 | 0.02% | $11.27K | 0.01% | Jun 30, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 311 | 0.00% | $213 | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -3,600 | -0.01% | -$3.17K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frank Bedu-Addo | President/CEO, Director | 866,050 | 1.55% | Mar 3, 2026 |
| Janetta Trochimiuk | Principal Accounting Officer | 1,124 | 0.00% | Sep 18, 2026 |
| Stephan Toutain | Chief Operating Officer | – | – | Mar 3, 2026 |
| Gregory Conn | Chief Scientific Officer | 115,545 | 0.21% | Mar 3, 2026 |
| Kirk V. Shepard | Chief Medical Officer | – | – | Mar 3, 2026 |
| Lars Boesgaard | Chief Financial Officer | – | – | Mar 3, 2026 |
| Spencer D. Brown | Senior VP, General Counsel | – | – | Mar 3, 2026 |
| Arnold James Banaag | Director | – | – | Sep 21, 2026 |
| Patrick Soon-Shiong | Director, 10% owner | – | – | Sep 21, 2026 |
| Kamil Ali-Jackson | Director | 11,764 | 0.02% | Mar 3, 2026 |
| Ilian Iliev | Director | – | – | Mar 3, 2026 |
| Otis W. Brawley | Director | – | – | Mar 3, 2026 |
| Gregory Gene Freitag | Director | 61,213 | 0.11% | Mar 3, 2026 |
| Stephen C. Glover | Director | 78,851 | 0.14% | Mar 3, 2026 |
| Nant Capital, LLC | 10% owner | 13,005,334 | 23.24% | Sep 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gregory Gene Freitag Director | Feb 28, 2025 | Buy | +15,060 | $1.66 | $25.00K | 61,213 |
| Stephen C. Glover Director | Feb 28, 2025 | Buy | +15,061 | $1.66 | $25.00K | 78,851 |
| Frank Bedu-Addo President/CEO, Director | Dec 2, 2022 | Option exercise | +219,535 | $6.57 | $1.44M | 866,050 |
| Frank Bedu-Addo President/CEO, Director | Dec 2, 2022 | Tax withholding | −175,184 | $9.78 | $1.71M | 690,866 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +100 | $9.00 | $900 | 3,975 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +100 | $9.00 | $900 | 4,075 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +400 | $8.90 | $3.56K | 3,875 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +2,500 | $9.00 | $22.50K | 3,475 |
| DeLyle W. Bloomquist – | Jun 16, 2021 | Option exercise | +2,970 | $5.99 | $17.79K | 183,888 |
| DeLyle W. Bloomquist – | Jun 16, 2021 | Buy | +10,000 | $9.88 | $98.80K | 193,888 |
| Voorhees Seth Van Chief Financial Officer | Jun 15, 2021 | Buy | +17,647 | $8.50 | $150.00K | 17,647 |
| Kamil Ali-Jackson Director | Jun 15, 2021 | Buy | +11,764 | $8.50 | $99.99K | 11,764 |
| Gregory Gene Freitag Director | Jun 15, 2021 | Buy | +5,882 | $8.50 | $50.00K | 46,153 |
| Stephen C. Glover Director | Jun 15, 2021 | Buy | +5,882 | $8.50 | $50.00K | 63,790 |
| Frank Bedu-Addo President/CEO, Director | Jun 15, 2021 | Option exercise | +53,174 | $6.57 | $349.35K | 673,681 |
| Frank Bedu-Addo President/CEO, Director | Jun 15, 2021 | Tax withholding | −27,166 | $12.86 | $349.35K | 646,515 |
| Gregory Gene Freitag Director | Feb 14, 2020 | Award | +38,400 | $1.30 | $49.92K | 40,271 |
| Stephen C. Glover Director | Feb 14, 2020 | Award | +38,400 | $1.30 | $49.92K | 57,908 |
| Richard Sykes Director | Feb 14, 2020 | Award | +384,615 | $1.30 | $500.00K | 445,108 |
| Andrew Saik Chief Financial Officer, Director | Feb 14, 2020 | Award | +38,400 | $1.30 | $49.92K | 42,549 |
| W. Bradford Middlekauff Senior VP, GC and Secretary | Mar 15, 2019 | Option exercise | +49,766 | – | – | 59,766 |
| James J. Loughlin Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 26,625 |
| R. Loch Macdonald Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 580,602 |
| Sol J. Barer Director | Mar 15, 2019 | Option exercise | +20,000 | – | – | 678,075 |
| Andrew Saik Chief Financial Officer | Mar 15, 2019 | Option exercise | +82,999 | – | – | 82,999 |
| Robert J. Spiegel Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 48,661 |
| Isaac Blech Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Brian A. Leuthner President and CEO, Director | Mar 15, 2019 | Option exercise | +169,032 | – | – | 239,268 |
| Isaac Blech Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Rosemary A. Crane Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Liam Ratcliffe Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Kurt G. Conti Director | Mar 23, 2018 | Other | −58,476 | – | – | 0 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 22, 2018 | Sale(10b5-1 plan) | −2,500 | $16.41 | $41.03K | 570,602 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 21, 2018 | Sale(10b5-1 plan) | −2,500 | $16.52 | $41.30K | 573,102 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 20, 2018 | Sale(10b5-1 plan) | −5,000 | $16.47 | $82.35K | 575,602 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 19, 2018 | Sale(10b5-1 plan) | −2,500 | $16.66 | $41.65K | 580,602 |
| Brian A. Leuthner President and CEO, Director | Mar 2, 2018 | Sale(10b5-1 plan) | −2,500 | $15.08 | $37.70K | 70,236 |
| Brian A. Leuthner President and CEO, Director | Mar 1, 2018 | Sale(10b5-1 plan) | −2,500 | $14.81 | $37.03K | 72,736 |
| Brian A. Leuthner President and CEO, Director | Feb 23, 2018 | Sale(10b5-1 plan) | −2,500 | $15.37 | $38.43K | 75,236 |
| Brian A. Leuthner President and CEO, Director | Feb 22, 2018 | Sale(10b5-1 plan) | −2,500 | $15.47 | $38.68K | 77,736 |
| R. Loch Macdonald Chief Scientific Officer, Director | Feb 22, 2018 | Sale(10b5-1 plan) | −2,500 | $14.49 | $36.23K | 583,102 |
| R. Loch Macdonald Chief Scientific Officer, Director | Feb 21, 2018 | Sale(10b5-1 plan) | −5,000 | $13.82 | $69.10K | 585,602 |
| R. Loch Macdonald Chief Scientific Officer, Director | Feb 20, 2018 | Sale(10b5-1 plan) | −5,000 | $13.75 | $68.75K | 590,602 |
| Brian A. Leuthner President and CEO, Director | Feb 2, 2018 | Sale(10b5-1 plan) | −2,500 | $12.96 | $32.40K | 80,236 |
| Brian A. Leuthner President and CEO, Director | Feb 1, 2018 | Sale(10b5-1 plan) | −2,500 | $13.14 | $32.85K | 82,736 |
| Brian A. Leuthner President and CEO, Director | Jan 3, 2018 | Sale(10b5-1 plan) | −2,500 | $10.11 | $25.28K | 85,236 |
| Brian A. Leuthner President and CEO, Director | Jan 2, 2018 | Sale(10b5-1 plan) | −2,500 | $10.11 | $25.28K | 87,736 |
| Brian A. Leuthner President and CEO, Director | Dec 5, 2017 | Sale(10b5-1 plan) | −2,500 | $9.68 | $24.20K | 90,236 |
| Brian A. Leuthner President and CEO, Director | Dec 4, 2017 | Sale(10b5-1 plan) | −2,500 | $9.97 | $24.93K | 92,736 |
| Brian A. Leuthner President and CEO, Director | Dec 1, 2017 | Sale(10b5-1 plan) | −2,500 | $9.92 | $24.80K | 95,236 |
| Albert N. Marchio Ii Chief Accounting & Adm Officer | Nov 22, 2017 | Sale | −3,361 | $10.00 | $33.61K | 0 |
| Brian A. Leuthner President and CEO, Director | Nov 3, 2017 | Sale(10b5-1 plan) | −2,500 | $10.86 | $27.15K | 97,736 |
| Brian A. Leuthner President and CEO, Director | Nov 2, 2017 | Sale(10b5-1 plan) | −2,500 | $10.94 | $27.35K | 100,236 |
| Brian A. Leuthner President and CEO, Director | Nov 1, 2017 | Sale(10b5-1 plan) | −2,500 | $10.92 | $27.30K | 102,736 |
| Brian A. Leuthner President and CEO, Director | Oct 4, 2017 | Sale(10b5-1 plan) | −2,500 | $11.14 | $27.85K | 105,236 |
| Brian A. Leuthner President and CEO, Director | Oct 3, 2017 | Sale(10b5-1 plan) | −2,500 | $10.93 | $27.33K | 107,736 |
| Brian A. Leuthner President and CEO, Director | Oct 2, 2017 | Sale(10b5-1 plan) | −2,500 | $10.81 | $27.03K | 110,236 |
| Brian A. Leuthner President and CEO, Director | Sep 6, 2017 | Sale(10b5-1 plan) | −2,500 | $10.31 | $25.78K | 112,736 |
| Brian A. Leuthner President and CEO, Director | Sep 5, 2017 | Sale(10b5-1 plan) | −2,500 | $9.94 | $24.85K | 115,236 |
| Brian A. Leuthner President and CEO, Director | Sep 1, 2017 | Sale(10b5-1 plan) | −2,500 | $10.37 | $25.92K | 117,736 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.